Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
Executive Summary
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.
You may also be interested in...
Pharma On The Hunt For Oncology Partners Across Modalities
The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.
Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D
Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.
Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.